What is Armata Pharmaceuticals?
Armata Pharmaceuticals is a clinical-stage biotechnology enterprise headquartered in Marina del Rey, California. Since its inception in 2005, the company has dedicated its research and development efforts to the creation of precisely targeted bacteriophage therapeutics. These innovative treatments are designed to combat complex, drug-resistant bacterial infections, a sector of healthcare that remains a high-priority area for medical advancement. By focusing on the unique biological mechanisms of phages, Armata aims to provide effective alternatives to traditional antibiotics, addressing a significant unmet need in modern medicine. The company's market position is defined by its specialized focus on high-precision, pathogen-specific therapies, which distinguishes it from broader pharmaceutical developers.
How much funding has Armata Pharmaceuticals raised?
Armata Pharmaceuticals has raised a total of $143.8M across 5 funding rounds:
Series A
$13.3M
Series D
$60.5M
Unspecified
$5M
Share Placement
$20M
Share Placement
$45M
Series A (2013): $13.3M, investors not publicly disclosed
Series D (2014): $60.5M led by Renaissance Holding Company
Unspecified (2014): $5M supported by Delta Dental of New Jersey
Share Placement (2021): $20M, investors not publicly disclosed
Share Placement (2022): $45M backed by Innoviva
Key Investors in Armata Pharmaceuticals
Innoviva
Innoviva is a diversified holding company with a portfolio of royalties and other healthcare assets. It partners with companies that advance innovative therapies for improving patient care and building long-lasting value.
Renaissance Holding Company
Renaissance Holdings is a prominent property developer recognized for its innovative and high-quality residential and commercial spaces, with a commitment to eco-friendly architecture and long-term value creation.
Delta Dental of New Jersey
Delta Dental of New Jersey is a leading dental benefits provider that also engages in strategic investments to support advancements in healthcare and wellness technologies.
What's next for Armata Pharmaceuticals?
With the recent capital injection, Armata Pharmaceuticals is expected to prioritize the advancement of its clinical trials and the expansion of its therapeutic candidate portfolio. The strategic focus will likely center on optimizing the delivery mechanisms for its bacteriophage treatments and navigating the regulatory pathways required for commercialization. Investors are closely monitoring the firm's ability to translate its scientific research into scalable, market-ready solutions. As the company continues to mature, the integration of these funds will be pivotal in sustaining its research momentum and potentially establishing new standards in the treatment of resistant bacterial pathogens. The firm's future success hinges on its ability to maintain its technological edge while demonstrating clinical efficacy in its ongoing and upcoming trials.
See full Armata Pharmaceuticals company page
